Your browser doesn't support javascript.
loading
Health-related quality of life, depressive symptoms, and chronic fatigue in long-term survivors of Hodgkin lymphoma.
Gulbrandsen, Monica S; Nøding, Ane S; Smeland, Knut B; Eikeland, Siri A; Kiserud, Cecilie E; Hjermstad, Marianne J; Fosså, Alexander.
Afiliación
  • Gulbrandsen MS; Department of Oncology, Oslo University Hospital, Oslo, Norway.
  • Nøding AS; Department of Oncology, Oslo University Hospital, Oslo, Norway.
  • Smeland KB; Department of Oncology, Oslo University Hospital, Oslo, Norway.
  • Eikeland SA; National Advisory Unit on Late Effects after Cancer Treatment, Department of Oncology, Oslo University Hospital, Oslo, Norway.
  • Kiserud CE; Department of Oncology, Oslo University Hospital, Oslo, Norway.
  • Hjermstad MJ; National Advisory Unit on Late Effects after Cancer Treatment, Department of Oncology, Oslo University Hospital, Oslo, Norway.
  • Fosså A; Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
Leuk Lymphoma ; 64(6): 1139-1150, 2023 06.
Article en En | MEDLINE | ID: mdl-37144290
High-dose chemotherapy with autologous stem cell transplantation (HDT-ASCT) is the preferred treatment option in relapsed or refractory Hodgkin lymphoma (HL). We analyzed the association between treatment intensity and health-related quality of life (HRQoL), depressive symptoms, and chronic fatigue (CF) in long-term survivors of HL (HLS), identified in two population-based national cross-sectional studies on late adverse effects. We included 375 HLS treated between 1987 and 2006, 264 with conventional therapy only, and 111 with HDT-ASCT. Despite similar differences to the matched general population, when controlling for other imbalances between the groups, use of HDT-ASCT was not associated with poorer outcome in multivariable analysis. However, work participation, family income, comorbidities, and lifestyle factors had stronger associations with aspects of HRQoL, depressive symptoms, and CF. Our data suggest that better rehabilitation to work participation and adequate income as well as follow-up for comorbidities may reduce differences in long-term outcome after treatment for HL.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Enfermedad de Hodgkin / Síndrome de Fatiga Crónica / Trasplante de Células Madre Hematopoyéticas Tipo de estudio: Diagnostic_studies / Etiology_studies / Observational_studies / Prevalence_studies / Prognostic_studies / Risk_factors_studies Aspecto: Patient_preference Límite: Humans Idioma: En Revista: Leuk Lymphoma Asunto de la revista: HEMATOLOGIA / NEOPLASIAS Año: 2023 Tipo del documento: Article País de afiliación: Noruega Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Enfermedad de Hodgkin / Síndrome de Fatiga Crónica / Trasplante de Células Madre Hematopoyéticas Tipo de estudio: Diagnostic_studies / Etiology_studies / Observational_studies / Prevalence_studies / Prognostic_studies / Risk_factors_studies Aspecto: Patient_preference Límite: Humans Idioma: En Revista: Leuk Lymphoma Asunto de la revista: HEMATOLOGIA / NEOPLASIAS Año: 2023 Tipo del documento: Article País de afiliación: Noruega Pais de publicación: Estados Unidos